Gambichler, T.; Mansour, R.; Scheel, C.H.; Said, S.; Abu Rached, N.; Susok, L.
Prognostic Performance of the Derived Neutrophil-to-Lymphocyte Ratio in Stage IV Melanoma Patients Treated with Immune Checkpoint Inhibitors. Dermato 2022, 2, 14-20.
https://doi.org/10.3390/dermato2020003
AMA Style
Gambichler T, Mansour R, Scheel CH, Said S, Abu Rached N, Susok L.
Prognostic Performance of the Derived Neutrophil-to-Lymphocyte Ratio in Stage IV Melanoma Patients Treated with Immune Checkpoint Inhibitors. Dermato. 2022; 2(2):14-20.
https://doi.org/10.3390/dermato2020003
Chicago/Turabian Style
Gambichler, Thilo, Rita Mansour, Christina H. Scheel, Shayda Said, Nessr Abu Rached, and Laura Susok.
2022. "Prognostic Performance of the Derived Neutrophil-to-Lymphocyte Ratio in Stage IV Melanoma Patients Treated with Immune Checkpoint Inhibitors" Dermato 2, no. 2: 14-20.
https://doi.org/10.3390/dermato2020003
APA Style
Gambichler, T., Mansour, R., Scheel, C. H., Said, S., Abu Rached, N., & Susok, L.
(2022). Prognostic Performance of the Derived Neutrophil-to-Lymphocyte Ratio in Stage IV Melanoma Patients Treated with Immune Checkpoint Inhibitors. Dermato, 2(2), 14-20.
https://doi.org/10.3390/dermato2020003
